Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Shinji Iwasaki, Yohei Kosugi, Andy Z.X. Zhu, Sayaka Nakagawa, Noriyasu Sano, Miyuki Funami, Mai Kosaka, Atsutoshi Furuta, Hideki Hirabayashi & Nobuyuki Amano. (2019) Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug–drug interactions using physiologically based pharmacokinetic modelling approach. Xenobiotica 49:11, pages 1251-1259.
Read now
Read now
Shinji Iwasaki, Hideki Hirabayashi & Nobuyuki Amano. (2018) Quantitative prediction of the extent of drug–drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes. Xenobiotica 48:8, pages 770-780.
Read now
Read now
Shinji Iwasaki, Hideki Hirabayashi, Miyuki Funami & Nobuyuki Amano. (2017) Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver. Xenobiotica 47:6, pages 488-497.
Read now
Read now
Maria Rosa, Pierre Bonnaillie & Hugues Chanteux. (2016) Prediction of drug–drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition. Xenobiotica 46:12, pages 1076-1084.
Read now
Read now
Yohei Kosugi, Hideki Hirabayashi, Tomoko Igari, Yasushi Fujioka, Teruaki Okuda & Toshiya Moriwaki. (2014) Risk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process. Xenobiotica 44:4, pages 336-344.
Read now
Read now
Nathalie Rioux, Joëlle Batonga, Federico Colombo, Jonathan Massé, Christine Zouki, Maria D. Ribadeneira, Jianmin Duan & Richard C. Bethell. (2013) A simplified approach to predict CYP3A-mediated drug–drug interactions at early drug discovery: validation with clinical data. Xenobiotica 43:7, pages 592-597.
Read now
Read now
Jackie Bloomer, Geo Derimanov, Etienne Dumont, Harma Ellens & Christopher Matheny. (2013)
Optimizing the and clinical assessment of drug interaction risk by understanding co-medications in patient populations
. Expert Opinion on Drug Metabolism & Toxicology 9:6, pages 737-751.
Read now
Read now
Hugh A Barton, Yurong Lai, Theunis C Goosen, Hannah M Jones, Ayman F El-Kattan, James R Gosset, Jian Lin & Manthena V Varma. (2013) Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opinion on Drug Metabolism & Toxicology 9:4, pages 459-472.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Justin D Lutz & Nina Isoherranen. (2012) In vitro-to-in vivo predictions of drug–drug interactions involving multiple reversible inhibitors. Expert Opinion on Drug Metabolism & Toxicology 8:4, pages 449-466.
Read now
Read now
Yohei Kosugi, Hideki Hirabayashi, Tomoko Igari, Yasushi Fujioka, Yoko Hara, Teruaki Okuda & Toshiya Moriwaki. (2012) Evaluation of cytochrome P450-mediated drug–drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica 42:2, pages 127-138.
Read now
Read now
Helen E. Cubitt, Karen R. Yeo, Eleanor M. Howgate, Amin Rostami-Hodjegan & Zoe E. Barter. (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:8, pages 623-638.
Read now
Read now
Andrea N Edginton & Ghanashyam Joshi. (2011) Have physiologically-based pharmacokinetic models delivered?. Expert Opinion on Drug Metabolism & Toxicology 7:8, pages 929-934.
Read now
Read now
Karen Rowland Yeo, Mohsen Aarabi, Masoud Jamei & Amin Rostami-Hodjegan. (2011) Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Review of Clinical Pharmacology 4:2, pages 261-274.
Read now
Read now
Odette A Fahmi & Sharon L Ripp. (2010) Evaluation of models for predicting drug–drug interactions due to induction. Expert Opinion on Drug Metabolism & Toxicology 6:11, pages 1399-1416.
Read now
Read now
T. Tachibana, M. Kato, T. Watanabe, T. Mitsui & Y. Sugiyama. (2009) Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:6, pages 430-443.
Read now
Read now
Masoud Jamei, Steve Marciniak, Kairui Feng, Adrian Barnett, Geoffrey Tucker & Amin Rostami-Hodjegan. (2009) The Simcyp® Population-based ADME Simulator. Expert Opinion on Drug Metabolism & Toxicology 5:2, pages 211-223.
Read now
Read now
U. Fagerholm. (2009) Presentation of a modified dispersion model (MDM) for hepatic drug extraction and a new methodology for the prediction of the rate-limiting step in hepatic metabolic clearance. Xenobiotica 39:1, pages 57-71.
Read now
Read now
Aleksandra Galetin, Michael Gertz & J Brian Houston. (2008) Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 909-922.
Read now
Read now
Articles from other publishers (26)
Ngoc‐Anh Thi Vu, Yun Min Song, Quyen Thi Tran, Hwi‐yeol Yun, Sang Kyum Kim, Jung‐woo Chae & Jae Kyoung Kim. (2023)
Beyond the
Michaelis–Menten
: Accurate Prediction of Drug Interactions Through Cytochrome
P450 3A4
Induction
. Clinical Pharmacology & Therapeutics 113:5, pages 1048-1057.
Crossref
Crossref
Zeyad Alehaideb. (2023) Prediction of herb-drug interactions involving consumption of furanocoumarin-mixtures and cytochrome P450 1A2-mediated caffeine metabolism inhibition in humans. Saudi Pharmaceutical Journal 31:3, pages 444-452.
Crossref
Crossref
Yomna M. Nassar, Nicolas Hohmann, Robin Michelet, Katharina Gottwalt, Andreas D. Meid, Jürgen Burhenne, Wilhelm Huisinga, Walter E. Haefeli, Gerd Mikus & Charlotte Kloft. (2022) Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion. Clinical Pharmacokinetics 61:11, pages 1595-1607.
Crossref
Crossref
Lien Thi Ngo, Sung‐yoon Yang, Sooyoung Shin, Duc Tuan Cao, Hung Van Nguyen, Sangkeun Jung, Jae‐Young Lee, Jong‐Hwa Lee, Hwi‐yeol Yun & Jung‐woo Chae. (2022)
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and
drug–drug
interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
. CPT: Pharmacometrics & Systems Pharmacology 11:11, pages 1430-1442.
Crossref
Crossref
Takashi Ueno, Yukiko Miyajima, Ishani Landry, Bojan Lalovic & Edgar Schuck. (2021) Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors. CPT: Pharmacometrics & Systems Pharmacology 10:5, pages 455-466.
Crossref
Crossref
Nadia Quignot, Witold Więcek, Leonie Lautz, Jean-Lou Dorne & Billy Amzal. (2021) Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment. Toxicology Letters 337, pages 111-120.
Crossref
Crossref
Michael Mohutsky & Stephen D. Hall. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
51
88
.
Bo Lindmark, Anna Lundahl, Kajsa P Kanebratt, Tommy B Andersson & Emre M Isin. (2018)
Human hepatocytes and cytochrome P450‐selective inhibitors predict variability in human drug exposure more accurately than human recombinant
P450s
. British Journal of Pharmacology 175:11, pages 2116-2129.
Crossref
Crossref
Michel Tod, Philippe B Pierrillas, Laurent Bourguignon & Sylvain Goutelle. (2016)
Comparison of the static
in vivo
approach to a physiologically based pharmacokinetic approach for metabolic drug–drug interactions prediction
. International Journal of Pharmacokinetics 1:1, pages 25-34.
Crossref
Crossref
Ioannis P. Androulakis. (2016) Quantitative Systems Pharmacology: A Framework for Context. Current Pharmacology Reports 2:3, pages 152-160.
Crossref
Crossref
Souzan B. Yanni. 2015. Translational ADMET for Drug Therapy. Translational ADMET for Drug Therapy
221
240
.
Souzan B. Yanni. 2015. Translational ADMET for Drug Therapy. Translational ADMET for Drug Therapy
139
178
.
X Han, SK Quinney, Z Wang, P Zhang, J Duke, Z Desta, JS Elmendorf, DA Flockhart & L Li. (2015) Identification and Mechanistic Investigation of Drug–Drug Interactions Associated With Myopathy: A Translational Approach. Clinical Pharmacology & Therapeutics 98:3, pages 321-327.
Crossref
Crossref
Heidi J. Einolf & Imad Hanna. 2014. Predictive ADMET. Predictive ADMET
353
396
.
Brian W. Ogilvie & Andrew Parkinson. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
21
.
X‐L Jiang, P Zhao, JS Barrett, LJ Lesko & S Schmidt. (2013) Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in Children. CPT: Pharmacometrics & Systems Pharmacology 2:10, pages 1-9.
Crossref
Crossref
Alexander V. LyubimovKarthik Venkatakrishnan. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
62
.
Alexander V. LyubimovHiroshi Komura & Masahiro Iwaki. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
41
.
. 2012. Pharmacokinetics and Metabolism in Drug Design. Pharmacokinetics and Metabolism in Drug Design
159
208
.
Guillaume Baneyx, Yumi Fukushima & Neil Parrott. (2012) Use of physiologically based pharmacokinetic modeling for assessment of drug–drug interactions. Future Medicinal Chemistry 4:5, pages 681-693.
Crossref
Crossref
Bill J. Smith. (2012) An industrial perspective on contemporary applications of PBPK models in drug discovery and development. Biopharmaceutics & Drug Disposition 33:2, pages 53-54.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
183
207
.
Cyrus Ghobadi, Trevor N. Johnson, Mohsen Aarabi, Lisa M. Almond, Aurel Constant Allabi, Karen Rowland-Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2011) Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients. Clinical Pharmacokinetics 50:12, pages 809-822.
Crossref
Crossref
Frédéric Y. Bois. (2010) Physiologically Based Modelling and Prediction of Drug Interactions. Basic & Clinical Pharmacology & Toxicology 106:3, pages 154-161.
Crossref
Crossref
Aleksandra Galetin & J. Brian Houston. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
315
343
.
Amin Rostami‐Hodjegan. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
549
568
.